Pre-made Enfortumab benchmark antibody ( Whole mAb ADC, anti-PVRL4/NECTIN4 therapeutic antibody, Anti-EDSS1/LNIR/PRR4/nectin-4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Enfortumab biosimilar, Whole mAb ADC, Anti-PVRL4/NECTIN4 Antibody: Anti-EDSS1/LNIR/PRR4/nectin-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enfortumab vedotin,[1] sold under the brand name Padcev, is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-182-1mg	1mg	4635
GMP-Bios-ab-182-10mg	10mg	Inquiry
GMP-Bios-ab-182-100mg	100mg	Inquiry
GMP-Bios-ab-182-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Enfortumab biosimilar, Whole mAb ADC, Anti-PVRL4/NECTIN4 Antibody: Anti-EDSS1/LNIR/PRR4/nectin-4 therapeutic antibody
INN Name	Enfortumab
Target	NECTIN4
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Agensys;Seattle Genetics
Conditions Approved	na
Conditions Active	Urogenital cancer
Conditions Discontinued	na
Development Tech	na